Current Surgical is developing a ‘smart’ needle designed to treat cancerous tumors

D.C.-based Current Surgical this week announced a $3.2 million seed. The round, which brings the firm’s total raise up to $4 million, was led by True Ventures and features 1517 Fund and SciFounders. It will be used, in part, to modestly grow the startup’s team, hiring between 6-8 engineers in the next 24 months, focused on a broad range of topics, including electrical, mechanical and ultrasound.

“This seed funding gives us the necessary capital to build out our team to develop the clinical embodiment of our device, which we can then test with our clinical collaborators in a preclinical setting,” the company tells TechCrunch. “We’ll also meet with the FDA to confirm regulatory protocols and tests for our technology.”

Current is working to produce a “smart needle,” designed to treat cancerous tumors, without more invasive surgery, which can harm surrounding organs, or chemotherapy and radiation, which bring their own respective drawbacks to the table.

Image Credits: Current Surgical